Jacobson Pharma Corporation Limited (HKG:2633)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Generic Drugs	1.58B	1.47B	1.27B	1.19B	1.05B
Generic Drugs Growth	7.43%	15.77%	6.40%	13.12%	-11.98%
Elimination of inter-segment revenue	-	-16.00K	-270.00K	-2.20M	-15.16M
Branded Healthcare	-	-	-	406.14M	407.70M
Branded Healthcare Growth	-	-	-	-0.38%	4.78%
Total	1.58B	1.47B	1.27B	1.60B	1.45B
Total Growth	7.43%	15.79%	-20.55%	10.35%	-7.99%

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Hong Kong	1.51B	1.42B	1.22B	1.43B	1.31B
Hong Kong Growth	6.56%	16.25%	-14.40%	8.81%	-9.16%
Mainland China	34.58M	33.39M	21.05M	79.97M	46.61M
Mainland China Growth	3.56%	58.57%	-73.67%	71.57%	35.41%
Macau	27.63M	12.90M	21.65M	59.62M	62.51M
Macau Growth	114.14%	-40.39%	-63.69%	-4.63%	9.63%
Others	99.00K	-	1.95M	14.96M	17.86M
Others Growth	-	-	-86.98%	-16.23%	-20.43%
Singapore	-	136.00K	225.00K	12.57M	6.19M
Singapore Growth	-	-39.56%	-98.21%	103.10%	-50.04%
Total	1.58B	1.47B	1.27B	1.60B	1.45B
Total Growth	7.43%	15.79%	-20.55%	10.35%	-7.99%

Source: S&P Global Market Intelligence.